

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formulation



Version 5.6 Revision Date: 04/09/2021 SDS Number: 26005-00017 Date of last issue: 10/16/2020
Date of first issue: 10/28/2014

SECTION 1. IDENTIFICATION

Product name : Mometasone Metered Dose Inhaler Formulation

Manufacturer or supplier's details

Company name of supplier : Organon & Co.
Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Gases under pressure : Dissolved gas

Reproductive toxicity : Category 1B

Simple Asphyxiant

GHS label elements

Hazard pictograms : 

Signal Word : Danger

Hazard Statements : H280 Contains gas under pressure; may explode if heated.
H360Df May damage the unborn child. Suspected of damaging fertility.
May displace oxygen and cause rapid suffocation.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves, protective clothing, eye protection and face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical attention.
Storage:
P405 Store locked up.
P410 + P403 Protect from sunlight. Store in a well-ventilated place.

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formulation



Version 5.6 Revision Date: 04/09/2021 SDS Number: 26005-00017 Date of last issue: 10/16/2020
Date of first issue: 10/28/2014

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Ethanol#	64-17-5	$\geq 1.8 - \leq 2.5$
Mometasone	83919-23-7	$\geq 0.08 - \leq 0.18$

Voluntarily-disclosed non-hazardous substance

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention immediately.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May damage the unborn child. Suspected of damaging fertility.
Gas reduces oxygen available for breathing.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
5.6	04/09/2021	26005-00017	Date of first issue: 10/28/2014

Unsuitable extinguishing media	:	Dry chemical None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health. If the temperature rises there is danger of the vessels bursting due to the high vapor pressure.
Hazardous combustion products	:	Carbon oxides Fluorine compounds
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Evacuate personnel to safe areas. Ventilate the area. Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
--------------------	---	---

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formula- tion



Version 5.6 Revision Date: 04/09/2021 SDS Number: 26005-00017 Date of last issue: 10/16/2020
Date of first issue: 10/28/2014

- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe vapors or spray mist.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep tightly closed.
Keep in a cool, well-ventilated place.
Store in accordance with the particular national regulations.
Do not pierce or burn, even after use.
Keep cool. Protect from sunlight.
- Materials to avoid : Do not store with the following product types:
Self-reactive substances and mixtures
Organic peroxides
Oxidizing agents
Flammable solids
Pyrophoric liquids
Pyrophoric solids
Self-heating substances and mixtures
Substances and mixtures which in contact with water emit flammable gases
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ethanol	64-17-5	TWA	1,000 ppm 1,900 mg/m ³	NIOSH REL
		STEL	1,000 ppm	ACGIH
		TWA	1,000 ppm 1,900 mg/m ³	OSHA Z-1
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm ²	Internal

Personal protective equipment

- Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formulation



Version 5.6 Revision Date: 04/09/2021 SDS Number: 26005-00017 Date of last issue: 10/16/2020
Date of first issue: 10/28/2014

unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Skin and body protection : Skin should be washed after contact.
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aerosol containing a dissolved gas

Color : white to off-white

Odor : odorless

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : 3 °F / -16 °C

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : 1 g/cm³

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formulation



Version 5.6 Revision Date: 04/09/2021 SDS Number: 26005-00017 Date of last issue: 10/16/2020
Date of first issue: 10/28/2014

Solubility(ies)
Water solubility : insoluble

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : If the temperature rises there is danger of the vessels bursting due to the high vapor pressure.
Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Ethanol:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): 124.7 mg/l

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formulation

Version 5.6 Revision Date: 04/09/2021 SDS Number: 26005-00017 Date of last issue: 10/16/2020
Date of first issue: 10/28/2014

Exposure time: 4 h
Test atmosphere: vapor

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.
LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation

Not classified based on available information.

Components:

Ethanol:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Mometasone:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ethanol:

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Method : OECD Test Guideline 405

Mometasone:

Species : Rabbit
Result : No eye irritation

Mometasone Metered Dose Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
5.6	04/09/2021	26005-00017	Date of first issue: 10/28/2014

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Ethanol:

Test Type	:	Local lymph node assay (LLNA)
Routes of exposure	:	Skin contact
Species	:	Mouse
Result	:	negative

Mometasone:

Test Type	:	Maximization Test
Routes of exposure	:	Dermal
Species	:	Guinea pig
Assessment	:	Does not cause skin sensitization.
Result	:	negative
Remarks	:	The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

Ethanol:

Genotoxicity in vitro	:	Test Type: In vitro mammalian cell gene mutation test
		Result: negative
Genotoxicity in vivo	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative
Genotoxicity in vivo	:	Test Type: Rodent dominant lethal test (germ cell) (in vivo)
		Species: Mouse
		Application Route: Ingestion
		Result: equivocal

Mometasone:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative
		Test Type: Chromosomal aberration
		Test system: Chinese hamster lung cells
		Result: negative
		Test Type: Chromosomal aberration
		Test system: Chinese hamster ovary cells

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formulation

Version 5.6 Revision Date: 04/09/2021 SDS Number: 26005-00017 Date of last issue: 10/16/2020
Date of first issue: 10/28/2014

Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years
Dose : 0.067 mg/kg body weight
Result : negative

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months
Dose : 0.160 mg/kg body weight
Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Mometasone Metered Dose Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
5.6	04/09/2021	26005-00017	Date of first issue: 10/28/2014

Components:**Ethanol:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Mouse
Application Route: Ingestion
Result: negative

Mometasone:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0.015 mg/kg body weight
Symptoms: Reduced embryonic survival, Reduced fetal weight.
Result: No effects on fertility., Effect on reproduction capacity.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Mouse
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 0.06 mg/kg body weight
Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-fetal development
Species: Rat
Application Route: Dermal
Embryo-fetal toxicity.: LOAEL: 0.3 mg/kg body weight
Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Dermal
Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed.

Test Type: Embryo-fetal development
Species: Rat
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
Result: Effects on newborn.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Embryo-fetal toxicity.: LOAEL: 0.7 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

Mometasone Metered Dose Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
5.6	04/09/2021	26005-00017	Date of first issue: 10/28/2014

STOT-single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

STOT-repeated exposure

Not classified based on available information.

Components:**Mometasone:**

Routes of exposure : inhalation (dust/mist/fume)
 Target Organs : Immune system, Liver, Kidney, Skin
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Ethanol:**

Species : Rat
 NOAEL : 1,280 mg/kg
 LOAEL : 3,156 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Mometasone:

Species : Rat
 NOAEL : 0.005 mg/kg
 LOAEL : 0.3 mg/kg
 Application Route : Oral
 Exposure time : 30 d
 Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
 LOAEL : 0.5 mg/kg
 Application Route : Oral
 Exposure time : 30 d
 Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat
 NOAEL : 0.00013 mg/l
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 90 d
 Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species : Dog

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
5.6	04/09/2021	26005-00017	Date of first issue: 10/28/2014

NOAEL : 0.0005 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 90 d
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

Components:

Mometasone:

Not applicable

Experience with human exposure

Components:

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact : Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:

Remarks : Dermal absorption possible

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ethanol:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l
Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia (water flea)): > 1,000 mg/l
Exposure time: 48 h
Toxicity to algae/aquatic plants : ErC50 (Chlorella vulgaris (Fresh water algae)): 275 mg/l
Exposure time: 72 h
EC10 (Chlorella vulgaris (Fresh water algae)): 11.5 mg/l
Exposure time: 72 h
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 9.6 mg/l
Exposure time: 9 d

Mometasone Metered Dose Inhaler Formulation

Version 5.6	Revision Date: 04/09/2021	SDS Number: 26005-00017	Date of last issue: 10/16/2020 Date of first issue: 10/28/2014
----------------	------------------------------	----------------------------	---

Toxicity to microorganisms : EC50 (*Pseudomonas putida*): 6,500 mg/l
Exposure time: 16 h

Mometasone:

Toxicity to fish : LC50 (*Menidia beryllina* (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.

LC50 (*Cyprinodon variegatus* (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

EC50 (*Americamysis*): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 0.00014 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0.34 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

**Mometasone Metered Dose Inhaler Formula-
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
5.6	04/09/2021	26005-00017	Date of first issue: 10/28/2014

Persistence and degradability**Components:****Ethanol:**

Biodegradability : Result: Readily biodegradable.
Biodegradation: 84 %
Exposure time: 20 d

Mometasone:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)
Method: OECD Test Guideline 111

Bioaccumulative potential**Components:****Ethanol:**

Partition coefficient: n-
octanol/water : log Pow: -0.35

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n-
octanol/water : log Pow: 4.68

Mobility in soil**Components:****Mometasone:**

Distribution among environ-
mental compartments : log Koc: 4.02

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste
handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.
Please ensure aerosol cans are sprayed completely empty

Mometasone Metered Dose Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
5.6	04/09/2021	26005-00017	Date of first issue: 10/28/2014

(including propellant)

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number	: UN 1950
Proper shipping name	: AEROSOLS
Class	: 2.2
Packing group	: Not assigned by regulation
Labels	: 2.2

IATA-DGR

UN/ID No.	: UN 1950
Proper shipping name	: Aerosols, non-flammable
Class	: 2.2
Packing group	: Not assigned by regulation
Labels	: Non-flammable, non-toxic Gas
Packing instruction (cargo aircraft)	: 203
Packing instruction (passenger aircraft)	: 203

IMDG-Code

UN number	: UN 1950
Proper shipping name	: AEROSOLS (Mometasone)
Class	: 2.2
Packing group	: Not assigned by regulation
Labels	: 2.2
EmS Code	: F-D, S-U
Marine pollutant	: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number	: UN 1950
Proper shipping name	: Aerosols
Class	: 2.2
Packing group	: Not assigned by regulation
Labels	: NON-FLAMMABLE GAS
ERG Code	: 126
Marine pollutant	: yes(Mometasone)

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
5.6	04/09/2021	26005-00017	Date of first issue: 10/28/2014

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Gases under pressure
Simple Asphyxiant
Reproductive toxicity

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

1,1,1,2,3,3,3-Heptafluoropropane	431-89-0
Ethanol	64-17-5

California List of Hazardous Substances

Ethanol	64-17-5
---------	---------

California Permissible Exposure Limits for Chemical Contaminants

Ethanol	64-17-5
---------	---------

International Regulations

Montreal Protocol : 1,1,1,2,3,3,3-Heptafluoropropane

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formulation


Version
5.6

Revision Date:
04/09/2021

SDS Number:
26005-00017

Date of last issue: 10/16/2020
Date of first issue: 10/28/2014

NFPA 704:



HMIS® IV:

HEALTH	*	0
FLAMMABILITY		1
PHYSICAL HAZARD		3

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / STEL	:	Short-term exposure limit
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); EC_x - Concentration associated with x% response; EHS - Extremely Hazardous Substance; EL_x - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErC_x - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC₅₀ - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC₅₀ - Lethal Concentration to 50 % of a test population; LD₅₀ - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-

SAFETY DATA SHEET



Mometasone Metered Dose Inhaler Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
5.6	04/09/2021	26005-00017	Date of first issue: 10/28/2014

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/09/2021

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8